Johnson & Johnson

Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour. The platform is made up of a tumour-targeting agent and a cancer therapeutic, which are activated via ‘click chemistry’. […]

Postdoctoral and clinical fellows are invited to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grant by June 21, 2023. This three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry, while allowing recipients to spend one year at a […]

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from […]

Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The […]

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of Covid-19. The […]